Tradestie Institutional Equity Comparison Engine

OBIO vs CVM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CVM Overall Edge

CVM Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cel-Sci Corporation (CVM) driven by superior Valuation, Growth & Margin while OBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
OBIO N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner CVM
Op Margin -195.4% vs 0.0% ยท YoY -89.4% vs -62.7%
Momentum & Technical Winner OBIO
1Y +76.9% vs -73.8% ยท 52W Pos 88% vs 14%
Options & Structure Winner OBIO
BREAKOUT (<1st %ile IV) vs BREAKDOWN (N/A IV)
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.97
-2.11% 1D
Market Cap $570.6M
1M Return +23.36%
1Y Return +76.9%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.85
+11.45% 1D
Market Cap $22.5M
1M Return +12.12%
1Y Return -73.76%
Forward P/E 23.0x
Unified AI Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OBIO +76.9% CVM -73.76% Spread: +148.95 pp (OBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OBIO Revenue CVM Revenue OBIO Op. Margin CVM Op. Margin Margin Edge
FY2011 N/A $0M N/A -1881.0% CVM
FY2012 N/A $0M N/A -6772.3% CVM
FY2013 N/A $0M N/A -12450.1% CVM
FY2014 N/A $0M N/A -9721.4% CVM
FY2022 $0M N/A -924.3% N/A OBIO
FY2023 $0M N/A -1866.2% N/A OBIO
FY2024 $0M N/A -2437.5% N/A OBIO
FY2025 $30M N/A -154.7% N/A OBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OBIO (4) vs CVM (6)
Institutional Metric OBIO CVM Criterion Row Winner
Market Capitalization Scale $570.6M $22.5M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY) Growth -89.4% -62.7% Higher Growth CVM
Operating Margin (TTM) Profitability -195.4% 0.0% Higher Margin CVM
Net Profit Margin Profitability -182.5% 0.0% Higher Margin CVM
Return on Equity (ROE) Capital Efficiency -182.3% -252.5% Higher ROE OBIO
52-Week Range Position Momentum 88% ($3โ€“$7) 14% ($1โ€“$8) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 80% Vol 0.42ฮฒ ยท 140% Vol Lower Realized Risk OBIO
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OBIO vs CVM Buy Guide
OBIO BREAKOUT
33d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OBIO nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.